The revolutionary impact of immune checkpoint inhibitors (ICIs) has transformed cancer care, yielding unprecedented durable responses across a spectru
Read Full Article To Earn PointsDaily news to keep you up to date
Participate and win exciting prizes
Participate and win cash vouchers
Get updates on the latest events happening around the world
1.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
2.
Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A
3.
Interleukin-6 may boost prediction of obesity-related cancers
4.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
5.
Compared to previous estimates, a greater number of patients participate in cancer treatment trials.
1.
Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern
2.
Role of Type I Interferons and KDM1B in Driving Cancer Stemness and Therapeutic Evasion
3.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
4.
Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition
5.
Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation